December 22, 2016 / 12:21 PM / 8 months ago

BRIEF-Genticel and Genkyotex intend to enter into strategic combination

Dec 22 (Reuters) - Genticel SA :

* Genticel and Genkyotex announce intention to enter into strategic combination

* Transaction would create a European group with a pipeline of first-in-class NOX inhibitors in fibrosis and inflammatory pain

* Transaction is subject to Genticel shareholders' approval during a general meeting to be held in Q1 2017

* Genkyotex's shareholders would receive 11.83551 new shares of Genticel for each share of Genkyotex contributed and hold 80 percent of share capital and voting rights of Genticel

* Combined consolidated cash position of Genkyotex and Genticel should enable new group to complete both its phase II study in PBC with GKT831 and its first phase I study with GKT771

* Phase 2 clinical trial in primary biliary cholangitis (PBC) to begin in H1 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below